We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Andrx Loses Race to File First Paragraph IV for J&J's Concerta
Andrx Loses Race to File First Paragraph IV for J&J's Concerta
August 9, 2005
Andrx was apparently a day late in its bid to secure marketing exclusivity for its generic version of Johnson & Johnson’s (J&J) attention-deficit/hyperactivity disorder treatment Concerta.